Ulcerative colitis

Fundraising events like this support research, education, and patient services for Crohn’s disease and ulcerative colitis. They also raise public awareness and honor people who contribute to the IBD community.

This research suggests genetic risk scores could help identify people with IBD who are more likely to have severe disease, which might eventually inform earlier monitoring or treatment decisions. It’s a step toward more...

Financial support programs can reduce education-related stress for students managing Crohn’s or colitis and recognize the challenges of juggling symptoms and school. If you or a family member with IBD are pursuing...

Fatigue affects a large majority of pediatric IBD patients and is linked to worse quality of life even when disease is in remission, so it’s a common problem families and clinicians will likely encounter. Understanding...

The episode clarifies key differences between Crohn’s and ulcerative colitis, outlines common symptoms that should prompt medical evaluation, and reviews monitoring and complication risks that affect long‑term care.

Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. Open the original article for the full...

Community events like this connect people with IBD to clinical expertise and peer support. Intestinal ultrasound is a monitoring tool many patients may hear more about and could discuss with their care team.

An interchangeable FDA approval can increase availability and potentially reduce costs for biologic treatments used in Crohn’s disease and ulcerative colitis. This may affect medication access, pharmacy substitution, and...

TREMFYA (guselkumab) is an IL-23 inhibitor being studied for ulcerative colitis and Crohn's disease; new trial data could affect future treatment options. For people with IBD, drug-development news may indicate upcoming...

Rising IBD cases, limited specialist access, and cultural differences in decision-making may delay diagnosis, worsen outcomes, and increase misinformation.

An interchangeable biosimilar to ustekinumab could expand access and lower costs for people with Crohn’s disease and ulcerative colitis who use Stelara. Pharmacists may be able to substitute the biosimilar for the...

Based on the title and source metadata, this appears to be a market or business news related to Ulcerative colitis, Crohn's disease, and Guselkumab. The original article is from firstwordpharma.com.

Clinical trials are how new IBD tests and treatments are developed; joining one can give access to interventions and helps improve care for people with Crohn’s disease or ulcerative colitis. The article gives practical...

An FDA interchangeability approval for a biosimilar to ustekinumab could make a lower-cost alternative more available for people with Crohn’s disease or ulcerative colitis who use Stelara. It’s primarily a regulatory and...

Formulary listings for Yesintek (ustekinumab biosimilar) could make an established IBD treatment more affordable and accessible for people with Crohn’s disease or ulcerative colitis. Wider payer coverage may affect which...

The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...

Genetic ancestry can influence IBD risk and disease course, and most prior studies focused on European populations.

People with IBD have a higher lifetime risk of colorectal cancer; updated UK guidelines give clinicians and patients evidence-based recommendations on when and how to do surveillance colonoscopy to detect precancerous...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from degruyterbrill.com.

Based on the title and source metadata, this appears to be an event or fundraiser related to Inflammatory bowel disease, Crohn's disease, and Ulcerative colitis. The original article is from patch.com.

Personal stories show how IBD affects daily life and mental health and point to local fundraising and community support opportunities. The article names a commonly used biologic (Remicade/infliximab) and describes...

This research looks at whether donor and patient diets can influence how well fecal microbiota transplants work. For people with IBD (including Crohn’s and ulcerative colitis), improving FMT success could mean better...

The study highlights racial and ethnic disparities in access to IBD care — including specialist visits, use of advanced therapies, and emergency services — which can affect disease management and outcomes. Recognizing...

Distinguishing Crohn’s from ulcerative colitis can be hard and often requires invasive tests. A reliable blood test would speed diagnosis and help patients start the right treatments sooner. This study is an early step...

ENTYVIO (vedolizumab) is a commonly used biologic for moderate-to-severe ulcerative colitis and Crohn’s disease — updates about its formulations, approvals, and market growth can affect access and availability.

This article reports on ENTYVIO (vedolizumab), a biologic used in Crohn's disease and ulcerative colitis, highlighting broader availability of a subcutaneous option and ongoing market growth—topics that can affect drug...

If you take biologic therapy for Crohn’s disease or ulcerative colitis, this study suggests brief overlaps when switching drugs may not increase infection risk, which could mean fewer gaps in treatment and less risk of...

Anaemia is common in children with IBD and can affect growth and cognitive development. Knowing how often it occurs, how severe it is, and how often it persists helps families and clinicians prioritize testing and...

This analysis suggests people with IBD (Crohn’s disease and ulcerative colitis) are more likely to have periodontitis. Oral health problems can worsen quality of life and may need separate screening or care.

Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...

Cure8 could only read part of this source from ajmc.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Vedolizumab, and Anti Integrin.

This study suggests LVV can occur in people with IBD at younger ages and with distinct vascular findings, and it may arise even when gut disease is in remission. That matters for awareness, diagnosis, and coordination...

Based on the title and source metadata, this appears to be a market or business news related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from...

A pooled analysis presented at a medical conference suggests people with IBD—especially ulcerative colitis—may have higher rates of some genitourinary cancers, which could affect discussions about cancer risk and...

This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.

Patients with IBD or new symptoms should understand that Crohn’s disease and ulcerative colitis can look very similar but affect different parts of the gut and may require different treatments. Accurate diagnosis matters...

If approved, TREMFYA (guselkumab) could become an additional IL‑23 inhibitor option for adults with moderate‑to‑severe Crohn’s disease, including both IV and SC induction dosing. That may affect treatment choices for...

A CHMP recommendation is a major regulatory step toward EU approval — that could mean a new biologic option (guselkumab/Tremfya) for adults with moderate–severe Crohn’s disease, including people who haven’t responded to...

A CHMP positive opinion means guselkumab (Tremfya) could become an approved treatment option for adults with moderately to severely active Crohn’s disease in the EU, offering both IV and SC induction routes. This could...

Based on the title and source metadata, this appears to be a biomarker study related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from msn.com.

This large observational study suggests that diets high in nutrient-dense plant foods (not processed plant products) were linked to lower risk of developing IBD and to fewer IBD-related surgeries. People with IBD often...

This approval adds an FDA-cleared IL-23 biologic (Tremfya) as a treatment option for adults with moderately to severely active Crohn’s disease, which may affect treatment choices. It also comes as multiple biosimilars to...

Cure8 could only read part of this source from benzinga.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Guselkumab.

An FDA approval means guselkumab (Tremfya) is now an authorized treatment option for adults with active Crohn’s disease. The drug offers both subcutaneous and IV induction choices and may be relevant for people who did...

A new FDA approval expands treatment options for adults with moderately to severely active Crohn’s disease, including a fully subcutaneous IL-23 inhibitor regimen that could offer more flexibility. The approval was based...

A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...

A newly FDA-approved biologic (guselkumab/Tremfya) offers another treatment option for adults with moderate to severe Crohn’s disease, including both IV and SC induction choices. This could matter for patients who have...

An FDA approval means a new, approved IL‑23 inhibitor option (guselkumab/TREMFYA) is available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices and offering a fully...